Media.Player

Hormone therapy for age-related muscle degeneration

Summary

Progressive muscle wasting is prevalent among the aging population. To date, the only treatment for sarcopenia—age-related loss of muscle fitness and strength—is regulation of diet and exercise. The blood circulating levels of the multifunctional, osteoblast-derived hormone osteocalcin decline with age, and this is thought to have an effect on the decline in muscle function. This technology utilizes osteocalcin as a treatment for age-related muscle loss and other degenerative muscular disorders, as well as a therapy for general improvement of muscle function.

Technology Benefits

There are no FDA-approved therapies for muscle wastingImproves muscle’s ability to metabolize glucose, synthesize proteins, and oxidize fatty acidsPatent Information:Patent Pending (WO/2016/081728)Tech Ventures Reference: IR CU15011

Technology Application

Treatment for sarcopenia, or age-related muscle wastingTreatment for cachexia, or illness related muscle-wastingTreatment for diabetes-related muscle atrophyTreatment for muscle atrophy from diseases such as muscular dystrophy, ALS, Guillian-Barre Syndrome, Dejerine–Sottas syndrome, Charcot-Marie-Tooth syndrome, multiple sclerosis

Detailed Technology Description

None

*Abstract

None

*Inquiry

Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

cu15011

*Principal Investigator

*Publications

Wei J, Karsenty G. ”An overview of the metabolic functions of osteocalcin.” Curr Osteoporos Rep. 2015 Jun;13(3):180-5.Karsenty G, Ferron M. “The contribution of bone to whole-organism physiology.” Nature. 2012 Jan 18;481(7381):314-20.Karsenty G1, Oury F. “Biology without walls: the novel endocrinology of bone.” Annu Rev Physiol. 2012;74:87-105.

Country/Region

USA